Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06562192 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
162
Enrollment target
20
Study locations

NCT06562192 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 162 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06562192, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
162 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Conditions Studied

Non-Small Cell Lung Cancer Colorectal Cancer Triple Negative Breast Cancer Pancreatic Ductal Adenocarcinoma HR+/HER2- Ductal and Lobular Breast Cancer

Interventions

  • DRUG [68Ga]Ga-NNS309
  • DRUG [177Lu]Lu-NNS309

Study Locations (20)

Other

  • Novartis Investigative Site - Brussels
  • Novartis Investigative Site - Bron
  • Novartis Investigative Site - Villejuif
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - München

California

  • University of California LA - Los Angeles
  • Stanford University Medical Center - Palo Alto

Michigan

  • BAMF Health - Grand Rapids
  • BAMF Health - Grand Rapids

Ontario

  • Novartis Investigative Site - Toronto
  • Novartis Investigative Site - Toronto

Quebec

  • Novartis Investigative Site - Montreal
  • Novartis Investigative Site - Montreal

Alabama

  • Uni of Alabama at Birmingham - Birmingham

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2024-10-15
Est. Completion 2031-01-16
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06562192

The ClinicalTrials.gov registry entry for NCT06562192 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which [68Ga]Ga-NNS309 is the first listed.

NCT06562192 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06562192 about?

NCT06562192 is a clinical study titled "Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers". The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small ce...

What is the current status of trial NCT06562192?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2024-10-15. Estimated completion is 2031-01-16.

What conditions does trial NCT06562192 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, HR+/HER2- Ductal and Lobular Breast Cancer.

What interventions are being tested in trial NCT06562192?

The interventions under investigation include: [68Ga]Ga-NNS309 (DRUG), [177Lu]Lu-NNS309 (DRUG).

Who is sponsoring clinical trial NCT06562192?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06562192 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.